Janux Therapeutics Inc (JANX) Price & Analysis

Compare

562 Followers

JANX Stock Chart & Stats

$16.51

-$2.71(-4.69%)

At close: Jan 08 4:00 PM EST

$16.51

-$2.71(-4.69%)

Day’s Range― - ―

52-Week Range$15.51 - $66.34

Previous CloseN/A

Volume1.13M

Average Volume (3M)1.96M

Market Cap

$993.04M

Enterprise Value$549.53M

Total Cash (Recent Filing)$988.99M

Total Debt (Recent Filing)$22.66M

Price to Earnings (P/E)―

Beta1.58

Next Earnings

Mar 06, 2026

EPS Estimate

-0.63

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.39

Shares Outstanding60,147,808

10 Day Avg. Volume3,579,452

30 Day Avg. Volume1,958,388

Financial Highlights & Ratios

PEG Ratio13.76

Price to Book (P/B)2.81

Price to Sales (P/S)271.80

P/FCF Ratio-65.15

Enterprise Value/Market Cap0.55

Enterprise Value/Revenue54.95

Enterprise Value/Gross Profit57.85

Enterprise Value/Ebitda-4.19

Forecast

1Y Price Target

$57.15

Price Target Upside246.15% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering17

EPS Forecast (FY)-1.95

Revenue Forecast (FY)$10.06M

Bulls Say, Bears Say

Bulls Say

Clinical Trial ResultsThe early PSA results from the Phase 1b cohort are overall directionally positive for where durability could land in a future data update.

Drug Efficacy And SafetyJANX007 is a viable drug with a reasonable safety profile and the potential to show a benefit in OS over Pluvicto, especially in the taxane-naïve mCRPC setting.

Financial PerformanceAnalyst's recommendation is shifting the 12-month price target on Janux to $60 per share.

Bears Say

Clinical Trial UncertaintyUncertainty remains on the pivotal trial design and timeline for JANX.

Competitive PositionThe stock's pullback is driven by a reduced competitive edge, as ORR and rPFS outcomes are now in line with Pluvicto.

Investor SentimentThe latest phase 1 update was admittedly mixed, and there was a -43% share move.

Janux Therapeutics Inc News

Midday Fly By; Kalshi hits $11B valuation, MongoDB reports Q3 beat

The major averages were broadly higher near noon, indicating some stabilization after yesterday’s pullback. Some of the gains...

6d ago

Janux Therapeutics falls -48.4%

Janux Therapeutics (JANX) is down -48.4%, or -$16.46 to $17.52. Published first on TheFly – the ultimate source...

6d ago

JANX

Janux Therapeutics falls -49.4%

Janux Therapeutics (JANX) is down -49.4%, or -$16.78 to $17.21. Published first on TheFly – the ultimate source...

6d ago

JANX

Janux Therapeutics price target lowered to $150 from $200 at Cantor Fitzgerald

Cantor Fitzgerald analyst Josh Schimmer lowered the firm’s price target on Janux Therapeutics (JANX) to $150 from $200...

6d ago

JANX

Janux Therapeutics price target lowered to $38 from $46 at Stifel

Stifel analyst Stephen Willey lowered the firm’s price target on Janux Therapeutics (JANX) to $38 from $46 and...

6d ago

JANX

Why Is Janux Therapeutics Stock (JANX) Crashing today?

Janux Therapeutics ($JANX) stock plunged 40% in Tuesday’s pre-market trading after the clinical-stage biopharmaceutical company announced “positive” interim...

6d ago

JANX

Janux Therapeutics price target lowered to $49 from $58 at BofA

BofA lowered the firm’s price target on Janux Therapeutics (JANX) to $49 from $58 and keeps a Buy...

6d ago

JANX

Janux Therapeutics price target lowered to $45 from $70 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Janux Therapeutics (JANX) to $45 from $70 and keeps a...

6d ago

JANX

Janux Therapeutics price target lowered to $32 from $80 at Clear Street

Clear Street lowered the firm’s price target on Janux Therapeutics (JANX) to $32 from $80 and keeps a...

6d ago

JANX

Closing Bell Movers: MongoDB jumps 22% on earnings beat and raise

After five consecutive winning days for U.S. indices, the first trading session of December got off to a...

7d ago

MDB

WMT

Janux Therapeutics down 46% at $18.50 after JANX007 Phase 1 data in mCRPC

18:08 EST Janux Therapeutics (JANX) down 46% at $18.50 after JANX007 Phase 1 data in mCRPC Published first...

7d ago

JANX

Optimistic Buy Rating for Janux Therapeutics Despite Challenges and Promising Market Potential

JonesTrading analyst Soumit Roy has reiterated their bullish stance on JANX stock, giving a Buy rating today. Soumit...

6d ago

JANX

Buy Rating Reaffirmed for JANX007 Amid Promising Survival Metrics and Competitive Positioning

In a report released today, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Janux...

6d ago

JANX

Buy Rating Affirmed for JANX007 Amid Promising Phase 1 Data and Market Dislocation

Janux Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Justin Zelin...

6d ago

JANX

JANX FAQ

What was Janux Therapeutics Inc’s price range in the past 12 months?

Janux Therapeutics Inc lowest stock price was $15.51 and its highest was $66.34 in the past 12 months.

What is Janux Therapeutics Inc’s market cap?

Janux Therapeutics Inc’s market cap is $993.04M.

When is Janux Therapeutics Inc’s upcoming earnings report date?

Janux Therapeutics Inc’s upcoming earnings report date is Mar 06, 2026 which is in 88 days.

How were Janux Therapeutics Inc’s earnings last quarter?

Janux Therapeutics Inc released its earnings results on Nov 06, 2025. The company reported -$0.39 earnings per share for the quarter, beating the consensus estimate of -$0.612 by $0.222.

Is Janux Therapeutics Inc overvalued?

According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Janux Therapeutics Inc pay dividends?

Janux Therapeutics Inc does not currently pay dividends.

What is Janux Therapeutics Inc’s EPS estimate?

Janux Therapeutics Inc’s EPS estimate is -0.63.

How many shares outstanding does Janux Therapeutics Inc have?

Janux Therapeutics Inc has 60,147,808 shares outstanding.

What happened to Janux Therapeutics Inc’s price movement after its last earnings report?

Janux Therapeutics Inc reported an EPS of -$0.39 in its last earnings report, beating expectations of -$0.612. Following the earnings report the stock price went down -7.606%.

Which hedge fund is a major shareholder of Janux Therapeutics Inc?

Currently, no hedge funds are holding shares in JANX

Janux Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-12.48%

Trailing 12-Months

Asset Growth

47.44%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Janux Therapeutics Inc

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. In addition, its EGFR-TRACTr is designed to target EGFR in many cancer types with multiple approved monoclonal antibodies. The company was incorporated in 2017 and is headquartered in La Jolla, California.

Janux Therapeutics Inc (JANX) Earnings & Revenues

Historic Earnings Reports

JANX Stock 12 Month Forecast

Average Price Target

$57.15

▲(246.15% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","86":"$86","151":"$151","53.5":"$53.5","118.5":"$118.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":150,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$150.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":57.15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$57.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,53.5,86,118.5,151],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.99,42.91384615384615,51.83769230769231,60.761538461538464,69.6853846153846,78.60923076923078,87.53307692307692,96.45692307692306,105.38076923076923,114.30461538461537,123.22846153846154,132.1523076923077,141.07615384615383,{"y":150,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.99,35.77153846153846,37.55307692307692,39.33461538461539,41.11615384615385,42.89769230769231,44.67923076923077,46.46076923076923,48.24230769230769,50.02384615384615,51.80538461538461,53.58692307692307,55.36846153846154,{"y":57.15,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,33.99,33.29846153846154,32.60692307692308,31.915384615384617,31.223846153846154,30.532307692307693,29.840769230769233,29.14923076923077,28.45769230769231,27.76615384615385,27.074615384615385,26.383076923076924,25.691538461538464,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.54,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.81,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.56,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.99,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >